An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence

Chang-Han Lee1,14, Tae Hyun Kang1,13,14, Ophélie Godon2, Makiko Watanabe1, George Delidakis1, Caitlin M. Gillis2, Delphine Sterlin2, David Hardy3, Michel Cogné4, Lynn E. Macdonald5, Andrew J. Murphy5, Naxin Tu5, Jiwon Lee6, Jonathan R. McDaniel1, Emily Makowski7, Peter M. Tessier8,9, Aaron S. Meyer10, Pierre Bruhns2,15* & George Georgiou1,11,12,15*

The pharmacokinetic properties of antibodies are largely dictated by the pH-dependent binding of the IgG fragment crystallizable (Fc) domain to the human neonatal Fc receptor (hFcRn). Engineered Fc domains that confer a longer circulation half-life by virtue of more favorable pH-dependent binding to hFcRn are of great therapeutic interest. Here we developed a pH Toggle switch Fc variant containing the L309D/Q311H/N434S (DHS) substitutions, which exhibits markedly improved pharmacokinetics relative to both native IgG1 and widely used half-life extension variants, both in conventional hFcRn transgenic mice and in new knock-in mouse strains engineered specifically to recapitulate all the key processes relevant to human antibody persistence in circulation, namely: (i) physiological expression of hFcRn, (ii) the impact of hFcyRs on antibody clearance and (iii) the role of competing endogenous IgG. DHS-IgG retains intact effector functions, which are important for the clearance of target pathogenic cells and also has favorable developability.

1Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA. 2Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM-75015, Paris, France. 3Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015 Paris, France. 4Limoges University, Limoges, France. 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. 6Thayer School of Engineering, Dartmouth College, Hanover, NH, USA. 7Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA. 8Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA. 9Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. 10Department of Bioengineering, University of California at Los Angeles, Los Angeles, CA, USA. 11Department of Molecular Bioscience, University of Texas at Austin, Austin, TX, USA. 12Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA. 13Present address: Department of Applied Chemistry, Kookmin University, Seoul, Republic of Korea. 14These authors contributed equally: Chang-Han Lee, Tae Hyun Kang. 15These authors jointly supervised this work: Pierre Bruhns, George Georgiou. *email: bruhns@pasteur.fr; gg@che.utexas.edu
IgG isotype antibodies avoid clearance by endolysosomal degradation by virtue of their pH-dependent binding to the neonatal Fc receptor (FcRn), which is expressed by cells in nearly every organ in mammals. The FcRn receptor consists of the glycosylated heavy α-chain polypeptide, an MHC I class family member which associates with β2-microglobulin (β2m). IgG internalized by pinocytosis binds to FcRn at endosomal pH (5.5-6.0) and as a result, instead of being directed to the endolysosomal compartment for degradation, IgG:FcRn complexes are sorted into tubules originating from sorting endosomes and directed to return to the plasma membrane. Upon fusion with the plasma membrane, the intracellular fluid within the tubules is released and rapidly equilibrates with the extracellular pH 7.4. At extracellular pH, the affinity of FcRn for the Fc domain is so low that antibodies are released back into circulation. This process occurs readily, despite the strong avidity effects of both the high local concentration of FcRn at the site of vesicle fusion, and the 2:1 stoichiometric binding of FcRn to IgG. Biophysical studies have elucidated the molecular details of the IgG:FcRn interaction, including the role of residues in the CH2–CH3 interface of the Fc domain in contact with FcRn, the pivotal role of His310 and His435 on pH-dependent binding, and the significance of protein dynamics.

Engineering the human Fc domain to improve pharmacokinetic (PK) properties (manifest as an increased area under the plasma drug concentration–time curve (AUC), a lower clearance rate and a longer β-phase T1/2) is of great interest for therapeutic purposes. Better PK enable less frequent administration and lower dosing, which in turn translate into improved patient compliance and lower costs. Mutations of the Fc domain that enhance the affinity for FcRn at both the endosomal and physiological pH have been shown to result in greater antibody clearance. In contrast, Fc mutations that preferentially enhance FcRn affinity at pH 5.8 confer increased antibody half-life in circulation. Domain combinations containing the amino acid substitutions M428L/N434S (LS mutant), M252Y/S254T/T256E (YTE mutant), or H433K/N434F (KF mutant) confer 10- to 12-fold higher affinity for FcRn at pH 5.8, result in the greatest reported increase in antibody half-life (2- to 4-fold in circulation) in mice and in non-human pri mates, and are currently being evaluated in multiple clinical trials. Notably, ravulizumab, a complement C5-inhibiting antibody containing the LS mutations, was FDA-approved for paroxysmal nocturnal hemoglobinuria and shown to have a serum half-life of ~49.7 days, and MED18897, a respiratory syncytial virus (RSV)-neutralizing antibody containing the YTE mutations, was shown to have a serum half-life of ~70 days, compared to approximately 20 days for wild-type (wt) IgG1, in infants in a phase 1b/2a study for prophylaxis against RSV infection.

While further improvements in human antibody PK are highly desirable, extensive protein engineering campaigns focused on identifying mutations that confer even higher affinity for FcRn at pH 5.8 relative to the YTE or LS Fc variants have so far failed to yield amino acid combinations capable of imparting even longer circulation half-life in animal models. Notably, YTE- and LS-Fc domains have significant binding to FcRn at pH 7.4 under high avidity conditions. Residual binding at pH 7.4 may have a negative effect on plasma recycling and circulation persistence. Another key consideration in the engineering of antibodies with ultra-long circulation half-life is that any mutation introduced into the Fc domain should not negatively impact other antibody characteristics such as effector functions or manufacturability. For example, the YTE, LS, and KF mutations reduce FcγR binding and effector functions to various degrees (depending on the mutant antibody and patient FcγR allotype), and the YTE mutations have been reported to also reduce complement-dependent cytotoxicity (CDC). Antibody PK are routinely evaluated in transgenic (Tg) mice overexpressing human FcRn (hFcRn) from non-native promoters. However, the currently available hFcRn Tg mouse models do not recapitulate many of the mechanisms that affect antibody clearance. Key limitations of the existing mouse models used for antibody PK studies arise from: (i) non-physiological levels of transgene hFcRn expression relative to mouse FcRn in wild-type animals; (ii) expression of mouse β2m instead of human β2m (hβ2m) in many of the currently used models; (iii) absence of endogenously produced human IgG to compete for FcRn binding, and (iv) no ability to account for the effect of binding to human FcγRs in clearance.

Here, we report the engineering of a human IgG Fc domain which, by virtue of having moderately higher affinity for FcRn at pH 5.8 but no detectable binding at pH 7.4 under high avidity conditions, confers improved antibody PK properties compared to the clinical stage YTE and LS variants, both in the commonly used hFcRn transgenic mouse model (hemizygotic 276) as well as in our new knock-in model (hFcRn-hβ2m–hFcγRs–hIgG1,κ mice). Importantly, we show that antibodies utilizing our engineered ultra-long half-life Fc domain display the full range of effector functions as the wt Fc domain while exhibiting far favorable biophysical properties for clinical development.

Results

Pharmacokinetics properties of an engineered human Fc variant. We developed a strategy that capitalizes on Escherichia coli display of large combinatorial IgG libraries (Anchored Peptide Expression (APEX) technology) for the isolation of clones expressing human IgG1 with mutated Fc domains that bind selectively to the human FcRn/human β2m complex (hFcRn–hβ2m) at pH 5.8 but not at pH 7.4 (Fig. 1a). Select regions of the human IgG1 Cγ2–Cγ3 hinge were combinatorially mutagenized (Supplementary Fig. 1a–c and Supplementary Table 1) to create a library of >10^8 transformants. Briefly, E. coli spheroplasts expressing mutated human IgG1 (Trastuzumab) anchored on the external leaflet of the inner membrane were first screened by FACS for binding to Alexa488-labeled hFcRn-hβ2m. Three rounds of FACS with hFcRn-hβ2m at pH 5.8 were performed to enrich antibodies with Fc domains with higher binding affinity at pH 5.8. The pool of clones enriched for enhanced binding at endosomal pH was then subjected to a competitive, two-step labeling process to eliminate variants that have detectable binding at pH 7.4. For this purpose, spheroplasted cells were labeled with an excess of Alexa647-labeled GST-hFcRn:hβ2m-Alexa488 (green) at pH 5.8, and clones with no ability to account for the effect of binding to human FcγRs in clearance were isolated (Supplementary Fig. 1d).

Antibody PK were analyzed in high-avidity conditions in mice (Fig. 1b). Antibody PK are highly desirable, extensive protein engineering campaigns focused on identifying mutations that confer even higher affinity for FcRn at pH 5.8 relative to the YTE or LS Fc variants. However, the currently available hFcRn Tg mouse models do not recapitulate many of the mechanisms that affect antibody clearance. Key limitations of the existing mouse models used for antibody PK studies arise from: (i) non-physiological levels of transgene hFcRn expression relative to mouse FcRn in wild-type animals; (ii) expression of mouse β2m instead of human β2m (hβ2m) in many of the currently used models; (iii) absence of endogenously produced human IgG to compete for FcRn binding, and (iv) no ability to account for the effect of binding to human FcγRs in clearance. To address these limitations, as part of this work we constructed new knock-in mouse models that express hFcRn, hβ2m, and hFcγRs, and, in addition, produce endogenously chimeric mouse–human IgG1, composed of mouse variable regions and human constant regions for the heavy and light chain. The resulting hFcRn Tg mice were characterized by improved antibody PK properties compared to the clinical stage YTE and LS variants, both in the commonly used hFcRn transgenic mouse model (hemizygotic 276) as well as in our new knock-in model (hFcRn-hβ2m–hFcγRs–hIgG1,κ mice).

Importantly, we show that antibodies utilizing our engineered ultra-long half-life Fc domain display the full range of effector functions as the wt Fc domain while exhibiting favorably improved biophysical properties for clinical development.
The four isolated antibody variants were produced in HEK293 cells. One variant, EDHY-IgG1 (V264E, L309D, Q311H, and N434Y), had a ~20-fold better affinity ($K_D, pH5.8 = 28 nM$) for hFcRn at pH 5.8 compared to wt IgG1 ($K_D, pH5.8 = 550 nM$) but also had residual binding at pH 7.4. A second variant, EDHS-IgG1 (V264E, L309D, Q311H, and N434S), had a ~6-fold increased affinity at 5.8 ($K_D, pH5.8 = 93 nM$) but no apparent binding at pH 7.4 (Supplementary Fig. 1e–g). Very extensive mutagenesis efforts aimed at identifying mutations conferring even better $K_D, pH5.8$ were unsuccessful, as all of the mutants isolated based on higher affinity at pH 5.8 had detectable binding at pH 7.4 based on FACS analysis.

Antibodies with the EDHS mutations in the Fc had drastically reduced binding to effector hFCyRs (Supplementary Fig. 1h), which was found to be due to the V264E mutation\(^\text{45}\). Since a V264E substitution has a minimal effect on hFcRn binding at pH 5.8 (ref. \text{48}), it was reverted back to a valine to yield the L309D/Q311H/N434S (DHS) Fc domain, resulting in complete recovery of hFCyR binding (Supplementary Fig. 1h). Moreover, these three amino acid substitutions did not affect the N-glycosylation pattern of the Fc domain which was comparable to that of wt IgG1 antibodies (Supplementary Fig. 2).

We performed a detailed analysis of the hFcRnβ2m-binding kinetics of DHS antibodies as a function of pH using SPR analysis with immobilized hFcRnβ2m at low, medium, or high density\(^\text{11}\) (500, 2000, or 4000 RU, Fig. 1b–d and Supplementary Fig. 3). Consistent with earlier reports\(^\text{49}\), YTE- and LS-IgG1 showed moderate and significant binding, at pH 7.4, respectively when SPR analysis was performed with medium or high hFcRnβ2m densities (Fig. 1b, c, Table 1). In contrast, we could detect no binding of DHS- or wt-IgG1 to hFcRnβ2m at physiological conditions at even the highest density tested (Fig. 1b).

The PK of Trastuzumab, which does not bind any mouse targets, formatted with DHS-, YTE-, LS-, or wt-IgG1 Fc domains were first evaluated in hemizygous hFcRn\(^\text{18}\) mice (hemizygotic Tg276), a widely used Tg mouse model for comparing the circulation persistence of human antibodies\(^\text{37}\). Following administration of a single intravenous dose (i.e. 2 mg/kg) by tail vein injection, the $\beta$-phase $T_{1/2}$ ($\beta$-phase half-life) of DHS was 2.0- and 3.1-fold higher compared to YTE and LS variants (290.9 ± 25.6 h

| Table 1 $K_D$ values for binding of DHS, YTE, LS variants or wt IgG1 to hFcRnβ2m dimer at pH 5.8 and 7.4 |
|-----------------|-----------------|-----------------|-----------------|
| $K_D$ (nM)      | pH 5.8          | pH 7.4          |
|-----------------|-----------------|-----------------|-----------------|
| Low density     | Medium density  | High density    |
|-----------------|-----------------|-----------------|-----------------|
| wt-IgG1         | 550 ± 50        | ND              | ND              |
| DHS-IgG1        | 110 ± 20        | ND              | ND              |
| YTE-IgG1        | 23 ± 1          | 4730 ± 480      | 4290 ± 310      |
| LS-IgG1         | 55 ± 3          | 946 ± 170       | 567 ± 152       |

All IgG variants analyzed with hFcRnβ2m dimer and their kinetic values were analyzed by the equivalent binding model. Data are presented as mean ± standard deviation from triplicate experiments.
compared to 148 ± 36.8 and 92.9 ± 6.1 h, respectively, data are presented as mean ± standard deviation). Total drug exposure over time for DHS-IgG1 (AUC_{int}) was 1.6-, 1.9-, and 5.3-fold greater relative to YTE-, LS-, and wt-IgG1 variants, respectively (Fig. 1d, Table 2). Antibody clearance followed biphasic kinetics, with a clearance rate of 0.11 ± 0.01 mL/day/kg for DHS-IgG1, approximately 6-fold lower than wt IgG1, and 1.9- and 2.2-fold lower than YTE- and LS-IgG1. Introduction of the DHS mutations into the Fc domain of IgG2, IgG3 (G3m16 allotype with H435 residue), or IgG4 subclasses also resulted in no detectable interaction with FcRn at pH 7.4, and likewise, conferred significantly improved PK for all the other three IgG subclasses (Fig. 1e–g, Supplementary Fig. 4, Supplementary Table 2). Collectively, our data: (a) reveal that the DHS Fc KI mouse strains: (i) the hFcRn:hIgG, competes with administered therapeutic antibodies for clearance, and (ii) Scarlett mice (Fig. 2i, Supplementary Fig. 5). Cell type-specific interaction for FcRn binding by circulating human IgG1 impacts the PK was 40% lower in the Scarlett mice underscoring how competitive for FcRn binding by circulating human IgG1 impacts the PK of administered antibodies in hFcRnKI mice.

Pharmacokinetic studies in novel knock-in mouse models. To more accurately evaluate antibody PK we constructed knock-in (KI) mouse models that account for multiple processes known to affect human IgG clearance and homeostasis (Fig. 2a–e). In these KI mouse strains: (i) the hFcRn:β2m complex is expressed in a manner that faithfully reexpresses the switch region of the mouse heavy-chain locus, thereby generating mice that exclusively produce human IgG1, which, unlike murine IgG, competes with administered therapeutic antibodies for FcRn binding and is produced endogenously. We developed a mouse in which the murine FcγR family is expressed to account for FcγR-dependent clearance, and finally, (iii) human IgG1, which, unlike murine IgG, competes with administered therapeutic antibodies for FcRn binding, is produced endogenously. We constructed a mouse in which the murine FcγR genes had been exchanged with the corresponding human genes, including introns and regulatory elements for FCGR1A and for FCGR2A, FCGR2B, FCGR2C, FCGR3A, and FCGR3B genes (hFcγRII substitutions reduce binding to the low-affinity FcγR in humans). The hFcγRII mice, intercrossed of VG6074 and VG1543 mice; Fig. 2a, b)51. The FcγR (mouse FcRn gene) was replaced with FCGR1T (mouse FcRn gene, VG1481; Fig. 2c) and the B2m (mouse β2m) gene was replaced with B2m (human β2m gene, VG5153; Fig. 2d). The hFcγRII hβ2mK1 hFcγR mice (designated as Marlene mice) were bred by crossing the four transgenes as shown in Fig. 2e. Finally, to account for the fact that endogenous mouse IgG does not compete with human IgG for binding to human FcRn52, the heavy-chain constant region of human IgG1 (IGHG1) was knocked-in to replace the switch μ region of the mouse heavy-chain locus, and the human kappa light-chain constant region (IGK) was knocked-in to replace the mouse kappa light-chain region (kappa light chains are used in 95% of circulating antibodies in mice), thereby generating mice that exclusively produce human IgG1 heavy chains, predominantly associated to human kappa light chains (Fig. 2f, g). The hFcγRII hβ2mK1 hFcγR K1 hIgG1, K1 mice (designated as Scarlett mice) were bred by crossing the Marlene and the hIgG1, K1 mice (Fig. 2h). hFcRn expression was confirmed by immune-histochemistry and RT-PCR of spleens of Scarlett mice (Fig. 2i, Supplementary Fig. 5). Cell type-specific expression of hFcyRs in Marlene and Scarlett is reported in Fig. 2j and Supplementary Fig. 6 is similar to that of humans, and consistent with our earlier reported expression pattern for hFcγRII mice50. Scarlett mice displayed 440 ± 120 μg/mL of human IgG1 in serum and undetectable levels of mouse IgG. The mouse IgG serum concentration in control C57BL/6J mice was 605 ± 147 μg/mL, in the same order of magnitude as human IgG1 in Scarlett mice.

We observed very comparable β-phase elimination half-life in the KI animals that produce endogenous human antibodies (Scarlett) for three different approved IgG1 antibodies (Trastuzumab, Rituximab, or Omalizumab) after a single intravenous dose (i.v. 2 mg/kg) by tail vein injection. Specifically, for Trastuzumab we compared the PK between the Scarlett mice and animals that do not have circulating human IgG1 (Marlene mice; Supplementary Fig. 7). The β-phase elimination half-life was 40% lower in the Scarlett mice underscoring how competition for FcRn binding by circulating human IgG1 impacts the PK of administered antibodies in hFcRnKI mice.

Consistent with the trends observed in the hemizygous Tg276 hFcRnKI mouse model, the data in Fig. 2k and Table 3 reveal that in Scarlett mice -DHS antibodies have ≥50% longer β-phase half-life (P ≤ 0.0001 to LS- or YTE-IgG1), a proportional increase in AUC_{int} (P ≤ 0.0001 to LS- or YTE-IgG1), and a proportional decrease in clearance rate (P ≤ 0.0001 to LS- or YTE-IgG1) relative to the YTE and LS variants. Compared to wt IgG1, the DHS mutations resulted in fourfold longer β-phase half-life and fivefold greater AUC_{int}.

**Table 2 Pharmacokinetic parameters for hemizygotic Tg276 hFcRn transgenic mice**

|                | AUC_{int} (μg days/mL) | Clearance (mL/day) | β-phase T_{1/2} (h) | V_{ss} (mL/kg) |
|----------------|------------------------|--------------------|---------------------|---------------|
| wt-IgG1        | 30.0 ± 1.6             | 0.66 ± 0.17        | 49.6 ± 13.4         | 1.50 ± 0.15   |
| DHS-IgG1       | 157.9 ± 3.4            | 0.11 ± 0.01        | 290.9 ± 25.6        | 0.59 ± 0.11   |
| YTE-IgG1       | 96.9 ± 3.3             | 0.24 ± 0.03        | 148.4 ± 36.8        | 0.72 ± 0.14   |
| LS-IgG1        | 84.4 ± 2.0             | 0.21 ± 0.03        | 92.9 ± 6.1          | 0.60 ± 0.06   |

Data are presented as mean ± standard deviation (n = 11).

**Effectors functions and biophysical properties of DHS-Fc.** Mutations that favorably impact antibody serum half-life can adversely affect binding to effector hFcyRs, in turn impairing the clearance of target cells by ADCC or ADCP53. Consistent with earlier reports, SPR measurements showed that the YTE mutations reduce binding to the low-affinity FcγRs (i.e. hFcyRIIA, hFcyRIIB, hFcyRIIIB) by more than threefold. The LS substitutions have a more modest effect on hFcyR binding, resulting in a twofold reduction in affinity for hFcyRI and hFcyRIIa, and threelfold reduction for hFcyRIIB_{v158}. In contrast, the affinities of the DHS-IgG1 for hFcyRs were statistically indistinguishable (or slightly improved in the case of hFcyRIIB_{v158}) compared to those of wt-IgG1 (Table 4, Supplementary Fig. 8a). Class-switched IgG2, IgG3, or IgG4 variants of Trastuzumab bearing DHS mutations also showed statistically indistinguishable binding to hFcyRs relative to their wt counterparts (Supplementary Fig. 8b). Not surprisingly, the in vitro ADCC activity of DHS-Trastuzumab IgG1 was identical to that observed with wt Trastuzumab in hFcyRIIa-V/V and -V/F donors, but greater than that of YTE-Trastuzumab IgG1 or LS-Trastuzumab IgG1 (Fig. 3a). On the other hand, as expected, with homozygotic hFcyRIIA-F/F donors, DHS-Trastuzumab IgG1 showed equivalent ADCC activities with wt Trastuzumab or LS-Trastuzumab IgG1 (Fig. 3a).

Next, we examined the ability of anti-CD20 (Rituximab) antibody variants to activate the classical complement pathway.

---

4 NATURE COMMUNICATIONS | (2019) 10:5031 | https://doi.org/10.1038/s41467-019-13108-2 | www.nature.com/naturecommunications
via the recruitment of Clq. Target cells (CD20⁺ Raji) opsonized with DHS-Rituximab IgG1 antibodies had a higher level of cell surface-deposed Clq relative to wt-, LS-, or YTE-Rituximab antibodies. DHS-Rituximab displayed twofold more potent CDC (0.7 ± 0.1 μg/mL) than wt- (1.5 ± 0.1 μg/mL) or LS-Rituximab (1.9 ± 0.1 μg/mL), and 10-fold more potent CDC than YTE-Rituximab, the latter which has already been reported to display significantly lower CDC activity than wt-Rituximab₁₈,₄₈ (Fig. 3b, c).

Rheumatoid factor (RF) refers to auto-antibodies that bind to the Fc domain of immunoglobulins. The binding of RF to therapeutic antibodies is associated with faster clearance and
**ARTICLE**

**Fig. 2** IgG pharmacokinetics in new knock-in mouse models. **a–h** Generation of knock-in mice for human FcγRs, FcRn, β2m, IgG1 heavy chain and kappa light chain constant regions: **a** humanization of the mouse low-affinity receptor locus; **b** humanization of the ectodomains of mouse FcγRI; **c** humanization of the ectodomains of mouse FcRn; **d** humanization of the mouse β2m gene (β2m); **e** breeding strategy to generate Marlene mice; **f** replacement of the switch μ region of the mouse heavy chain locus by the constant region of human IgG1 heavy chain (IGHG1); **g** humanization of the kappa light chain gene (IGK); **h** breeding strategy to generate Scarlett mice; **a–d, f–g** representations are not drawn to scale. Coordinates are based on mouse (GRCm38,p4) and human (GRCh38,p7) genomic assemblies; mouse genes are in empty rectangles, genomic coordinates are in black; human genes are in solid rectangles, genomic coordinates are in gray, black triangles represent LoxP sites. mb, exon encoding the transmembrane and intracytoplasmic domains; H, exon encoding the hinge domain; Neo, selection cassette. Mouse silhouette was created by co-author P.B.

**Table 3** Pharmacokinetic parameters for Scarlett (hFcRnKI hIgG1, hFcγRIIaKI hlgG1, κKI) mice

| Cmax (mg/mL) | AUC_{inf} (μg days/mL) | Clearance (mL/day) | t1/2 (h) | Vss (mL/kg) |
|-------------|------------------------|-------------------|----------|-----------|
| wt-lgG1     | 29.9 ± 9.2             | 74.8 ± 7.35       | 0.27 ± 0.03 | 92.1 ± 12.3 | 0.65 ± 0.04 |
| DHS-lgG1    | 45.6 ± 18.4            | 356.8 ± 16.7      | 0.084 ± 0.006 | 236.8 ± 20.8 | 0.33 ± 0.02 |
| YTE-lgG1    | 35.5 ± 11.6            | 238.1 ± 15.9      | 0.090 ± 0.009 | 255.0 ± 31.8 | 0.36 ± 0.02 |
| LS-lgG1     | 40.2 ± 12.6            | 223.0 ± 24.1      | 0.062 ± 0.010 | 305.0 ± 38.8 | 0.30 ± 0.02 |

Data are presented as mean ± standard deviation (n = 6).

**Table 4** K_{0} values for human FcγRs determined by SPR

| K_0 (μM) | FcγRI (x10^{-2}) | FcγRIIa_{H131} | FcγRIIa_{G131} | FcγRIIb | FcγRIIa_{Fv} | FcγRIIa_{Vv} |
|-----------|------------------|----------------|----------------|---------|--------------|--------------|
| wt-lgG1   | 0.21 ± 0.02      | 0.22 ± 0.06    | 1.16 ± 0.25    | 2.64 ± 0.39 | 1.17 ± 0.23 | 0.17 ± 0.04 |
| DHS-lgG1  | 0.28 ± 0.02      | 0.27 ± 0.04    | 0.95 ± 0.02    | 2.91 ± 0.54 | 0.48 ± 0.07 | 0.18 ± 0.03 |
| YTE-lgG1  | 0.29 ± 0.02      | 0.62 ± 0.18    | 3.20 ± 0.26    | 6.24 ± 0.10 | 4.41 ± 0.93 | 0.82 ± 0.11 |
| LS-lgG1   | 0.58 ± 0.12      | 0.41 ± 0.30    | 1.21 ± 0.02    | 2.25 ± 0.03 | 0.64 ± 0.09 | 0.52 ± 0.09 |

All IgG variants analyzed with monomeric Fc receptors and their kinetic values were analyzed by the equivalent binding model. Data are presented as mean ± standard deviation from triplicate experiments.

**Fig. 3** Features of DHS Fc variants relevant to therapeutic antibody development. **a** ADCC assay of SK-BR-3 with PBMCs from FcγRIIa V/V, V/F, or F/F donors. **b** C1q deposition on CD20^+ Raji cells revealed by flow cytometry. **c** CDC assay of Rituximab-Fc variants with Raji cells as a function of antibody concentration. **d** Binding to rheumatoid factor (RF) measured by ELISA. P values by two-way ANOVA test, *P ≤ 0.05 and **P ≤ 0.001. **k** Change in serum IgG concentration following tail vein administration of 2 mg/kg of antibody in Scarlett (hFcRnKI hIgG1, hFcγRIIaKI hlgG1, κKI) mice (n = 6). Data are presented as mean ± standard deviation from triplicate experiments.
increased antigen presentation and anti-drug antibodies. We measured the RF binding of the wt-, DHS-, YTE-, and LS-IgG1 by ELISA using polyclonal sera from donors with high RF titers. DHS-IgG1 showed binding to RF sera that was indistinguishable from that of wt-IgG1 and significantly lower than that observed with YTE-IgG1 and especially with LS-IgG1 (Fig. 3d).

Size exclusion chromatography (SEC) showed that for all four IgG subclasses, introduction of the DHS mutations did not affect protein solubility nor did it lead to soluble aggregate formation (Supplementary Fig. 9a). The thermodynamic stability of therapeutic antibodies is one of the most important biophysical properties for clinical development. The melting temperature ($T_m$) was comparable for the wt, DHS, and LS Fc variants (Table 5) but was more than 6 °C lower for the YTE variant (Table 5). The susceptibility of the antibody variants to aggregation at 70 °C was very high for YTE-IgG1, leading to visible precipitates within minutes, intermediate for LS-IgG1, and minimal for wt- and DHS-IgG1 (Supplementary Fig. 9b–e).

Similarly, the YTE- and LS-IgG1 formed higher levels of soluble aggregates upon prolonged incubation at 50 °C (Fig. 3e). Finally, the self-association propensity of the various engineered Fc antibodies at room temperature was determined by affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS), a widely used assay for antibody developability. Earlier AC-SINS analyses using 137 FDA-approved antibody drugs found that AC-SINS plasmon shifts $>11.8$ nm correspond to antibodies with high levels of self-association and which represents a development risk. For DHS-IgG1 the AC-SINS plasmon shift was only $0.1 \pm 0.5$ nm; of note, YTE- and LS-antibodies also showed low plasmon shift in this assay albeit higher than that of DHS-IgG1 (Fig. 3f).

Discussion

An ideal Fc domain for therapeutic applications must confer optimal pH-dependent binding to hFcRn to achieve very long circulation half-life, maintain intact effector functions, and display favorable biophysical properties suitable for clinical development. To enable maximal antibody circulation half-life, an Fc domain should resemble a pH toggle switch with a low FcRn $K_{D_{pH6.8}}$ and no detectable binding activity at pH 7.4. However, despite extensive efforts, engineering Fc domains with a lower FcRn $K_{D_{pH6.8}}$ and no detectable binding at pH 7.4 under high avidity conditions had proven elusive. Here, we used a two-step high-throughput screening strategy to isolate the DHS Fc variant, which has a fivefold lower $K_{D_{pH6.8}}$ for FcRn relative to wt-IgG1 Fc and no detectable binding at pH 7.4. Unlike antibodies containing the YTE or LS half-life extension mutations, the DHS Fc domain does not bind to high densities of immobilized hFcRn at pH 7.4 (Fig. 1b, c, Table 1). We found that, by virtue of the lack of detectable binding at pH 7.4 and despite having a lower affinity for FcRn at endosomal pH relative to the LS or YTE variants, DHS antibodies exhibit even more favorable pharmacokinetics in multiple mouse models. Specifically, as shown in Fig. 1d and Table 2, the DHS Fc domain confers significantly improved antibody PK properties relative to the YTE and LS variants in hemizygous Tg276 mice, a widely used model for antibody PK studies. In the Tg276 model, hFcRn is transcribed from the CAG promoter, resulting in ubiquitous high-level gene expression. A second transgenic mouse line, Tg32, in which hFcRn is under the control of the human hFcRn promoter, is also commonly used for antibody PK studies; however, in this model the transgene is inserted in close proximity to a mouse enhancer region which in turn impacts transcription and tissue-specific expression. Because neither model fully recapitulates mouse endogenous FcRn expression, we constructed new models in which hFcRn and hIgG1 are expressed from the respective mouse promoters. The binding of antibodies to FcγRs, and in particular to FcγRs expressed by liver-resident cells, is known to affect antibody clearance. However, since human antibodies bind to mouse FcγRs with very different affinities than those of their human counterparts, the effect of FcγR-mediated clearance of human IgG cannot be properly accounted for in animals expressing murine IgG receptors. To address this shortcoming, we further engineered hFcRnKO hIgG1 and hIgM1 mouse to also express all the human FcγR family proteins (Marlene mice). Yet another factor that plays an important role for therapeutic antibody PK is the competition for hFcRn binding by endogenous, circulating human IgG. Because mouse IgG does not bind to hFcRn in some earlier antibody PK studies in Tg276 or Tg32 hFcRnKO mice intravenous co-administration of IgG (IVIG) was attempted as a surrogate for endogenous IgG competition. However, the effect of IVIG was reported to be dependent on the mouse model and was more pronounced in animals expressing lower hFcRn levels. To overcome these problems, we further engineered the Marlene mice to express chimeric mouse-human IgG1 containing the constant regions of human IgG1 heavy chain and human kappa light chain. The resulting Scarlett mouse strain displayed circulating human IgG1 concentrations comparable to those of mouse IgG1 in C57BL/6J mice. We note however that even though the Scarlett model produce levels of human IgG1 comparable to what is physiologically relevant for mouse IgG1, it may nonetheless somewhat underestimate the impact of competing IgG1 in humans due to species differences since humans produce higher levels of this antibody isotype. Beyond their utility in comparing the PK of different half-life extension variants as shown here, these new knock-in models are likely to prove particularly useful for preclinical studies for the understanding of antibody effector functions in mice that express physiologically relevant levels of FcγRs and additionally express competing endogenous IgG1.

Consistent with the improved PK properties of antibodies with the DHS mutations compared to antibodies with the clinical-stage YTE and LS variants in Tg276 hemizygous mice in Fig. 1d and Table 2, the DHS amino acid substitutions resulted in ≥50% increase of $\beta$-phase $T_{1/2}$ and $AUC_{Inf}$ in the Scarlett model. The relative improvement in the PK parameters of DHS antibodies compared to the YTE or LS variants in the Scarlett model was lower than the effect (twofold) observed in Tg276 and may be due to competition by IgG, the impact of effector FcγR clearance mechanisms and possibly, mouse strain background differences. If, as expected, the PK behavior of antibodies in Scarlett mice more closely mimics that in humans, the observed 50% greater $\beta$-phase half-life and drug exposure afforded by the DHS mutations should result in significant therapeutic benefit. For example, a 50% improvement over YTE antibodies could be expected to translate into a circulation half-life in humans of well over 100 days.

| Table 5 Tm measurement by differential scanning fluorimetry (DSF) |
|------------------|------------------|
| $T_m$ (°C)       |
| wt-Fc            | 69.0 ± 0.2       |
| DHS-Fc           | 70.2 ± 0.2       |
| YTE-Fc           | 62.4 ± 0.2       |
| LS-Fc            | 67.9 ± 0.2       |

Data are presented as mean ± standard deviation ($n = 3$). Lee et al. report an engineered IgG1 Fc domain that behaves like an hFcRn binding pH toggle switch. The authors show that this new half-life extension Fc domain confers improved pharmacokinetics in new humanized knock-in mouse strains that recapitulate the key processes for antibody persistence in circulation.

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13108-2 | www.nature.com/naturecommunications
To quantitatively explore the significance of endosomal retention (determined by $K_D$ at pH 5.8) versus surface recapture (determined by the $K_D$ at pH 7.4) we constructed a simple phenomenological PK model (Supplementary Fig. 10). This model is sufficient to explain the relative PK properties of each Fc domain. Sensitivity analysis indicates that surface recapture is the dominant parameter limiting circulation persistence of YTE- and LS-IgG1 mutants. Specifically, in the hemizygotic Tg276 mice as well as in the Scramble mice, the consequence of residual affinity of these Fc domains at the extracellular pH is roughly 50% or 20% recapture, respectively, of antibody on the cell surface during endosomal recycling. Collectively, both experimental PK parameter and the quantitative modeling of antibodies with distinct hFcRn-binding properties at endosomal and physiological pH highlighted the negative effect of hFcFcrn binding at pH 7.4 on antibody circulation persistence.

Fc-mediated effector functions (ADCC and CDC), developability (biophysical properties including thermodynamic stability), and drug bioavailability (serum half-life) of therapeutic antibodies are of critical importance for clinical application of therapeutic antibodies.\textsuperscript{8,64} We demonstrate herein that the DHS Fc variant has (i) intact Fc-mediated effector functions, (ii) a similar Tn, low aggregation propensity, no evidence for self-association and low binding to RF, similar to wt IgG1 antibodies, and (iii) ultra-long circulation persistence in highly relevant new humanized mouse models.

**Methods**

**Cells and reagents.** Adrenocarcinoma SK-BR3 cell line (ATCC® HTB-30™) and Raji cell line (ATCC® CCL-86™) were obtained from American Type Culture Collection. SK-BR3 was cultured in complete Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS). Human PBMCs were purified from anonymous healthy volunteers using histopaque density gradient centrifugation (Sigma-Aldrich). Human C1q (CompTech) and hFcRn:h2m-Alexa488 were purchased. All primers were synthesized by Integrated DNA Technologies.

**Preparation of recombinant proteins.** Human Fc receptors, including hFcRn, hFcRnF, hFcRnRb, and hFcRnV2m, were cloned in-frame into the mammalian expression vector pcDNA3.4 using Gibson Assembly cloning (NEB)\textsuperscript{44} and were produced by transient transfection of Expi293 cells (Invitrogen) according to the manufacturer’s instruction.\textsuperscript{45,46,66} His-tagged Fc receptor proteins were purified with Glutathione Sepharose (GE Healthcare) affinity columns according to the manufacturer’s instructions. In order to remove lipopolysaccharide (LPS) and non-specifically bound protein, the Fc receptor-bound resins were washed with 50 mL of PBS containing 0.1% Triton-X-114 (Sigma-Aldrich) and 50 mL of PBS. His-tagged Fc receptor proteins were eluted with PBS containing 250 mM imidazole and GST-tagged Fc receptor proteins were eluted with PBS containing 10 mM reduced L-glutathione. The buffer in the Fc receptor protein containing eluent fraction was exchanged with PBS by Amicon Ultra-30 centrifugal spin columns (Millipore). Similarly, isolated Fc candidates were cloned in-frame into the mammalian expression vector pcDNA3.4-Igh-Trastuzumabum using Gibson Assembly cloning (NEB)\textsuperscript{46} and were produced in Expi293 cells (Invitrogen) grown for 5 days at 37°C with 8% CO2. All IgG variants proteins purified by Protein A high capacity agarose resin (Thermo Scientific) according to the manufacturer’s instructions. Purity of antibody variants was confirmed by SDS-PAGE and size exclusion chromatography and was over 95%.

**Library construction and screening.** Amino acid residues D249-R255, V308-Q438 in the Fc that are within 7 Å distance from FcRn in the crystal structure of the human FcFcrn complex (PDB ID: 4N0U)\textsuperscript{13} were selected for mutagenesis using the aa substitution scheme shown and three separate libraries were constructed using primers with degenerate codons (Supplementary Table 1). The heavy chain of trastuzumab IgG1 was used as the template. The amplified PCR fragments were digested with FspI restriction sites for the histidine encoding library. The resulting plasmids were transformed into E. coli JDF1 [Tn5(Tet’)] proAB lacI Delta[as2][M15] mcrA Delta(mvr-hdr-mRS-mcrBC) [dalaZAM15 slaZ74 deor mcrA araD139 (ara leu)7697 galU galK] (Invitrogen). A library of 1 x 10^6 transformants was obtained. The transformants were spheroplasted after overnight induction with 1 mM of IPTG and 0.2% of l-arabinose, followed by phenol-chloroform extraction, 10 mM of hFcRn:h2m, conjugated with the second antibody Alexa488 (hFcRn:h2m-Alexa488) as a target probe, at pH 5.8 in PBS. Screening was performed using a FACS Aria™ (BD Biosciences). In each round, the top 3% of the population showing the highest fluorescence was collected and the spheroplasts were re-sorted immediately to remove false positives. The transformants with the plasmids of sorted spheroplasts were prepared. After four rounds, in order to achieve pH-selective binding activity, the library was first labeled with 5 nM of GST-hFcRn:h2m-Alexa647 at neutral pH, then incubated with 10 nM of hFcRn:h2m-Alexa488 at pH 5.8 (Fig. 1a). After the fifth round, single Fc variants were analyzed with pH-dependent-binding activities by flow cytometry and the four candidates were isolated.

**LC-ESI-MS/MS analysis of Fc variants**. Fc proteins were analyzed by The University of Texas at Austin Proteomics Facility using LC-MS on Thermo Orbitrap Fusion Tribrid mass spectrometer with the FT detector. A fast gradient of 0.1% formic acid/water and 0.1% formic acid/acetonitrile over 10 min was used to elute the intact proteins from an OPTI-TRAP™ protein microtrap (Optimize Technologies). The Orbitrap Fusion was operated in Intact Protein Mode at 15,000 resolution from 400 to 2000 m/z. The data were deconvoluted using Thermo Protein Deconvolution software.

**Size exclusion chromatography.** SEC analyses for the purified IgG proteins were performed on an AKTA Pure (GE Healthcare) liquid chromatography system using a Superdex 200 10/300HC, (GE Healthcare), with a mobile phase of pH 7.4 PBS at a flow rate of 0.75 mL/min. Chromatograms were obtained by monitoring the absorbance at 280 nm. The injection amount was 100 μg of proteins in a volume of 200 μL. For thermal stress test, each antibody protein (1 mg/mL) was incubated at 70°C for 10, 20, 40, and 60 min and then analyzed by SEC using the above described method.

**Differential scanning fluorimetry.** Differential scanning fluorimetry (DSF) was performed with SYPRO Orange dye (Catalog #8-6650, Life Technologies) to determine the thermal stability by monitoring the protein unfolding of the purified Fc domains. For each sample, 15 μL of Fc domains varying from 0.08 to 20 μM were mixed with 5 μL of dye, diluted from 5000X to 20X for use. Each experiment included a control without proteins containing 100 mM HEPEs buffer at pH 7. The DSF assays were performed on an Applied Biosystems ViiA 7 Real-Time PCR System using a temperature gradient from 25 to 99°C at a temperature ramp rate of 0.03°C/s. The fluorescence emissions and melting temperature measurements were analyzed using ViiA 7 Software from Life Technologies.

**AC-SINS.** Goat anti-human Fc fragment specific (Jackson ImmunoResearch, 109-005-008) was buffer exchanged into 20 mM potassium acetate (pH 4.3) twice using Zeba desalting columns (Thermo Fisher Scientific, PI-89882). The goat anti-human Fc concentration was evaluated using UV absorbance value at 280 nm (extinction coefficient 138000 M⁻¹ cm⁻¹) and 100 μg/mL of goat Fc antibody in the acetate buffer. Equal volumes of goat anti-human Fc antibody and gold nanoparticles (Ted Pella, 15705-1) were incubated at room temperature (1 h). The antibody-gold conjugates (3 mL) were loaded onto 0.22 μm filters (Millipore Sigma, SLGV013SL, PVDF) in 50 mL of PBS. Goat-Fc antibody-gold conjugates (50 μL) were added to the filter cartridges to elute the gold conjugates, which typically resulted in recovery of ~100 μL per cartridge. The concentrated conjugates were mixed well by pipetting up and down ten times. The conjugates (5 μL) were added first to a 384-well polystyrene plate (Thermo Fisher, 12-565-506), and then the PBS control or test antibodies (in PBS, 45 μL) were added. The samples were mixed well by pipetting up and down ten times. The absorbance spectra were measured (450-650 nm) in 1 nm increments using a Bioteck Synergy Neo microplate reader (BioTek, Winooski VT). The plasma wavelengths were calculated by fitting a second order polynomial equations to the 40 absorbance measurements surrounding the maximum absorbance values and selecting those wavelengths to the polymers to zero. The plasma shifts were calculated as the difference in the plasma wavelengths of the test antibodies relative to the PBS control (no human antibody).

hFcFcrn KD determination using surface plasmon resonance. For SPR analysis, IgG1 antibody variants were immobilized on CM5 chip surface at a density of ~500 response units (RU) via an amine coupling. hFcRn:h2m dimer (Novus Biologicals) was injected at serially diluted concentrations (1000–40 μM) in PBS with a flow rate of 30 μL/min. To examine the interaction of hFcRn and antibody variants at physiological pH 7.4, hFcRn:h2m dimer (Novus Biologicals) was immobilized on the BIACore Chip at three different densities, 500 RU, 2000 RU, and 4000 RU via amine coupling\textsuperscript{45}. Serially diluted antibodies (800–50 nM) were injected in PBS, pH 7.4, at a flow rate of 30 μL/min. Dissociation constants ($K_D$) were determined by fitting the corresponding binding isotherms for steady-state data or by fitting the kinetics for association and dissociation employing a 1:1 Langmuir mass transfer model. In addition, to detect the function of pH for hFc:

"ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13108-2 | www.nature.com/naturecommunications"
according to the following formula:

$$w = \frac{[\text{fluorescence of experimental well}]}{\text{fluorescence of a well } C} \times \left( \frac{M_e}{M} \right)$$

where $E$ is the fluorescence of experimental well, $S$ is the fluorescence of a well containing tumor cells and complement but no antibody, and $M$ is the fluorescence of a well containing tumor cells with lysis buffer (Triton X-100 at 2% v/v, SDS 1% w/v, 100 mM NaCl, and 1 mM EDTA). As an isotype control, Rituximab was used.

**Ctq deposition assay.** Raji cells were resuspended in 25% human serum and then incubated with the serially diluted Rituximab-Fc variants at 37 °C for 30 min. Classical complement activation reactions were then quenched with 20 volumes of ice-cold 1% BSA-PBS. The cells were pelleted, washed once, and then probed with FITC anti-Ctq (Abcam) for 30 min at 4 °C. The samples were washed and analyzed by flow cytometry.

**CDC assay.** For CDC assay, Raji cells were labeled with 4 μM Calcein AM (Life Technologies, USA) in PBS at 37 °C under 5% CO2 for 4 h. The released calcein AM was detected at excitation and emission wavelengths of 485 and 535 nm. The percent of tumor cell lysis was calculated using the following formula:

$$100 \times \left( 1 - \frac{S}{M} \right)$$

where $S$ is the fluorescence of an isotype control with GoTaq G2 polymerase (Promega). Amplification was performed by 35 cycles PCR each consisting of 94 °C for 1 min, 58 °C for 1 min, and 72 °C for 1 min. At the end of the 35 cycles, samples were run for an additional 10 min at 72 °C and analyzed by 1.5% agarose gel electrophoresis.

**Pharmacokinetics studies in mice.** Animals were administered a bolus intravenous (i.v.) dose of 2 mg/kg antibody on day 0 by tail vein injection. Blood samples were obtained from the tail vein using capillary pipettes at different time points. Serum concentration of antibody in Tg276, Marlene, or Scarlett was measured using a quantitative ELISA as follows: 96-well plates were coated with 2 μg of goat anti-human F(ab’)2 fragment-specific F(ab’)2 (for Tg276; Jackson Immunoresearch) or 1 μg of each antibodies (for Marlene and Scarlett). Her2 extracellular domain protein (Antibodies-Onice) for trastuzumab, CD20 linear peptide (142—184, extracellular domain) for rituximab, or IgE protein for omalizumab was used. Plates were blocked with 1% Fish gelatin (AMRESCO Inc) in PBS for 1 h, and then incubated with appropriately diluted serum samples (1:200 for earlier time points and 1:50 or 1:100 for later time points). Anti-kappa light chain antibody-HRP (Abcam) was used to detect the human antibody (dilution 1:5,000). Absorbance at 450 nm was measured after development with TMB substrate (Pierce Biotechnology, Rockford, IL) according to the manufacturer’s directions. Standard curves were generated for each antibody variant diluted into 1:100 pre-bleed mouse serum. The linear portions of standard curves generated in Prism (GraphPad Software) were then used to quantify human IgG1 in the serum samples.

Pharmacokinetic parameters were analyzed with two-compartment elimination model. $AUC_{\text{inf}}$ (area under the curve to infinity) was calculated using the log-linear trapezoidal method 20. Terminal half-life ($t_{1/2}$) was calculated using the log-linear trapezoidal method 20. Terminal half-life ($t_{1/2}$) was calculated using

$$V_D = \frac{Dose \times AUC_{\text{inf}}}{C_0}$$

Volumes of distribution at steady state were calculated using the following equation:

$$V_D = \frac{Dose \times AUC_{\text{inf}}}{(C_0 \times C_{\text{inf}})}$$

Computational modeling. All analysis was implemented in R and Stan, and can be found at [https://github.com/meyer-lab/FcRn-trafficking], release 1.0.
Exogenous IgG is modeled to exchange between three compartments representing a central extracellular, peripheral extracellular, and endosomal space. The central compartment is modeled as

\[
\frac{dC_C}{dt} = Q(C_P - C_C),
\]

where \(C_C\), \(C_P\), and \(C_e\) indicate the central, peripheral, and endosomal compartment concentrations, respectively, in units of \(\mu\text{g/mL}\). \(Q\) indicates the transport rate between these two compartments in units of the central compartment volume per hour. As the entire model scales proportionally, the central compartment volume \(V_C\) was assumed to equal 1, and all volumes are specified in relative amounts. The peripheral compartment concentration was specified as

\[
\frac{dC_P}{dt} = QeC_C - QC_P - QsC_e + QC_0\text{f}_{\text{release}},
\]

where \(V_P\) and \(V_e\) are the peripheral and endosomal volumes (relative to the central compartment volume), and \(Qs\) is the rate of uptake into cells in units of central compartment volume per hour. \(f_{\text{release}}\) indicates the fraction of endosomal IgG that is recycled, and \(f_{\text{release}}\) indicates the fraction of IgG presented to the cell surface that is released (as opposed to endocytosed again).

\[
\frac{dC_e}{dt} = QsC_p + (1 - f_{\text{release}})f_{\text{sort}} - 1).
\]

Implicit in this model are a few assumptions: First, there is no clearance outside of cellular uptake and lysosomal degradation. Each sorting fraction and model parameter is assumed to not vary with the concentration of exogenous IgG, therefore assuming that the modeled processes are not saturable. Finally, sorting and release are assumed to vary in the same order as their measured affinities at pH 5.8 and 7.4, with IgG of no measurable affinity at 7.4 fully released \(f_{\text{release}} = 1\).

The resultant linear ODE model was solved using the matrix exponential of the Jacobian. The half-life was found through root finding with Newton’s method. Prior to \(V_P\), \(Q_P\), and \(V_P\) were all specified as log-normal distributions with a mean and deviation of 1 in their respective units. The prior for \(Q_s\) was specified as a log-normal distribution with mean \(\mu_1\) and deviation of 0.5. Sorting parameter priors were specified to be flat and constrained to be in the order dictated by their relative affinity measurements. For example, if species A had a higher endosomal affinity than B, then \(f_{\text{sort}}\) was given an even prior from 0 to 1, and \(f_{\text{sort}}\) was given an even prior from 0 to \(f_{\text{sort}}\). The half-life of each species was compared to a normal distribution representing the average and standard error of the in vivo experimental measurements. Sampling convergence was verified through autocorrelation analysis and the Geweke criterion.

**References**

1. Ghetie, V. et al. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. *Annu. Rev. Immunol.* 18, 739–766 (2000).
2. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. *Nat. Rev. Immunol.* 7, 715–725 (2007).
3. Ward, E. S., Devanaboyina, S. C. & Ober, R. J. Targeting FcRn for the modulation of antibody dynamics. *Mol. Immunol.* 67, 131–141 (2015).
4. Pyzik, M., Rath, T., Lencer, W. I., Baker, K. & Blumberg, R. S. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. *J. Immunol.* 194, 4595–4603 (2015).
5. Roopenian, D. C. et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. *J. Immunol.* 170, 3528–3533 (2003).
6. D’Hooghe, L., Chalmers, A. D., Heywood, S. & Whitley, P. Cell surface dynamics and cellular distribution of endogenous FcRn. *PloS One* 12, e0182695 (2017).
7. Challa, D. K., Velmurugan, R., Ober, R. J. & Sally Ward, E. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. *Curr. Top. Microbiol. Immunol.* 382, 249–272 (2014).
8. Lencer, W. I. & Blumberg, R. S. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. *Trends Cell Biol.* 15, 5–9 (2005).
9. Sánchez, L. M., Penny, D. M. & Bjorkman, P. J. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. *Biochemistry* 38, 9471–9476 (1999).
10. Abdiche, Y. N. et al. The neonatal Fc receptor (FcRn) binds independently to class I-related receptor FcRn. *J. Biol. Chem.* 291, 1817–1825 (2016).
11. Martin, W. L., West, A. P. Jr., Gan, L. & Bjorkman, P. J. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. *Mol. Cell* 7, 867–877 (2001).
12. Oganesyan, V. et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. *J. Biol. Chem.* 289, 7812–7824 (2014).
13. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. *Drug Discov. Today* 17, 419–424 (2012).
14. Kamath, A. V. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. *Drug Discov. Today Technol.* 21–22, 75–83 (2016).
15. Zalesky, J. et al. Enhanced antibody half-life improves in vivo activity. *Nat. Biotechnol.* 28, 157–159 (2010).
16. DallAcqua, W. F. et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. *J. Immunol.* 169, 5171–5180 (2002).
17. DallAcqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgGis engineered for enhanced binding to the neonatal Fc receptor (FcRn). *J. Biol. Chem.* 281, 23514–23524 (2006).
18. Strohl, W. R. Current progress in innovative engineered antibodies. *Protein Cell* 9, 86–120 (2018).
19. Borrok, M. J. et al. pH-dependent binding engineering reveals an FcRn affinity threshold which governs IgG recycling. *J. Biol. Chem.* 2014 https://doi.org/10.1074/jbc.M114.603712.
20. Datta-Mannan, A. et al. Increasing the affinity of a human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. *Drug Metab. Dispos.* 40, 1545–1555 (2012).
21. Zhau, Q. et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. *Sci. Transl. Med.* 9, https://doi.org/10.1126/scitranslmed.aai2919 (2017).
22. Ko, S.-Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHF infection. *Nature* 514, 642–645 (2014).
23. Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R. J. & Ward, E. S. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. *Proc. Natl. Acad. Sci. USA* 103, 18709–18714 (2006).
24. FDA approved. PNH treatment. https://www.ultomiris.com/?gclid=CKj4vf-9QcQFChMhlT2spNysK5qVUL7Ac7hOr3ANREAAYASAEgyptANPD_Bwe.
25. Domachowska, J. et al. Safety, tolerability, and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. *Pediatr. Infect. Dis. J.* https://doi.org/10.1097/INF.0000000000001916 (2018).
26. Datta-Mannan, A., Witcher, D. R., Tang, Y., Watkins, J. & Wroblewski, V. J. Monoclonal antibody clearance impact of modulating the interaction of IgG with the neonatal Fc receptor. *J. Biol. Chem.* 282, 1709–1717 (2007).
27. Datta-Mannan, A. et al. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. *Drug Metab. Dispos.* 35, 86–94 (2007).
28. Zhau, Q. et al. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical to phase I study. *Clin. Pharmacol. Ther.* 89, 283–290 (2011).
32. Cooper, P. R. et al. The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups. Front. Pharmacol. 8, 207 (2017).
33. Wang, W. et al. Monoclonal antibodies with identical fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab. Dispos. 39, 1469–1477 (2011).
34. Borrok, M. J. et al. An ‘Fc-Silenced’ IgG1 format with extended half-life designed for improved stability. J. Pharm. Sci. 106, 1008–1017 (2017).
35. Greys, A. et al. Fc engineering of human IgG for altered binding to the neonatal Fc receptor affects Fc effector functions. J. Immunol. 194, 5497–5508 (2015).
36. Roopenian, D. C., Christianson, G. J., Proetzel, G. & Sproule, T. J. in Proc. Natl Acad. Sci. USA, 104, 1253–1258 (2007).
37. Jarasch, A. et al. Developability assessment during the selection of novel Fc variants. Methods 65, 148–153 (2014).
38. Latvala, S., Jacobsen, B., Ottenden, M. B., Herrmann, A. & Kronenberg, S. Distribution of FcRn across species and tissues. J. Histochem. Cytochem. 65, 321–333 (2017).
39. Andersen, J. T., Daba, M. B., Berntzan, G., Michaelisen, T. E. & Sandlie, I. Cross-species binding analysis of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem. 285, 4826–4836 (2010).
40. Tam, S. H., McCarthy, S. G., Brosnan, K., Goldberg, K. M. & Scallon, B. J. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. mAbs 5, 397–405 (2013).
41. Kasturirangan, S. et al. Targeted Fcy receptor (FcγR)-mediated clearance by a biparatopic bispeci fity antibody. J. Biol. Chem. 292, 4361–4370 (2017).
42. Khare, P. et al. Myeloid oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model. J. Autoimmun. 95, 115–125 (2018).
43. Jung, S. T. et al. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcRγIIα affinity and selectivity. ACS Chem. Biol. 8, 368–375 (2012).
44. Lee, C.-H. et al. IgG Fc domains that bind C1q but not effector Fc receptors delineate the importance of complement-mediated effector functions. Nat. Immunol. 18, 889–898 (2017).
45. Harvey, R. B. et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc. Natl Acad. Sci. USA 101, 9193–9198 (2004).
46. Kang, T. H. et al. An engineered human Fc variant with exquisite selectivity for FcγRIIIα/V158 reveals that ligation of FcγRIIIα mediates potent antibody dependent cellular phagocytosis with GM-CSF-differentiated macrophages. Front. Immunol. 10, 562 (2019).
47. Yu, X. et al. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J. Am. Chem. Soc. 135, 9723–9732 (2013).
48. Monnet, C. et al. Selection of IgG variants with increased FcRn binding using random and directed mutagenic impact on effector functions. Front. Immunol. 6, 39 (2015).
49. Greys, A. et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat. Commun. 9, 621 (2018).
50. Gillis, C. M. et al. Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice. J. Allergy Clin. Immunol. 139, 1253–1265 (2017).
51. Becherer, H. et al. Platelets expressing IgG receptor FcγRII/CD32A determine the severity of experimental anaphylaxis. Sci. Immunol. 3, eaan5997 (2018).
52. Bruhns, P. et al. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640–5649 (2012).
53. Zwaal, R. F. J. in Advances in Immunology (eds. Dixon, F. J. & Kunkel, H. G.) vol. 16, 265–336 (Academic Press, 1973).
54. Ingegnoli, F., Castelli, R. & Guaitterotti, R. Rheumatoid factors: clinical applications. Dis. Markers 35, 727–734 (2013).
55. Newkirk, M. M. Rheumatoid factors: host resistance or autoimmunity? Clin. Immunol. 104, 1–13 (2002).
56. Lee, D. M. et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297, 1689–1692 (2002).
57. Jarasch, A. et al. Developability assessment during the selection of novel therapeutic antibodies. J. Pharm. Sci. 104, 1885–1898 (2015).
58. Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944–949 (2017).
59. Sale, S. V., Dickinson, C. D., Lu, J., Chow, C.-K. & Tessier, P. M. Rapid analysis of antibody self-association in complex mixtures using immunoglobulin conjugates. Mol. Pharm. 10, 1322–1331 (2013).
60. Liu, Y. et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. mAbs 6, 483–492 (2014).
61. Bruhns, P. et al. Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716–3725 (2009).
62. Overdijk, M. B. et al. Crossoptalk between human IgG isoforms and murine effector cells. J. Immunol. 189, 3430–3438 (2012).
63. Stein, C. et al. Clinical chemistry of human FcRn transgenic mice. Mamm. Genome. 23, 259–269 (2012).
64. Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M. & Penichet, M. L. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Front. Immunol. 8, 1751 (2018).
65. Peng, Y., Gong, R. & Dimitrov, D. S. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor. Protein Expr. Purif. 79, 66–71 (2011).
66. Kelton, W. et al. IgGA: a ‘cross-isotype’ engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem. Biol. 21, 1603–1609 (2014).
67. Kawarasaki, Y. et al. Enhanced crossover SCRATCHY: construction and high-throughput screening of a combinatorial library containing multiple non-homologous crossovers. Nucleic Acids Res. 31, e126 (2003).
68. Chaudhury, C. et al. The major histocompatibility complex-related Fc receptor (FcγRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197, 315–322 (2003).
69. Carpenter, B. Starc: a probabilistic programming language. J. Stat. Softw. https://doi.org/10.18637/jss.v076.i01.

Acknowledgements

We thank Y. Tanno for assistance with protein expression and M. Tisch with immuno-histochemistry assay. This work was supported by the Clayton Foundation, by the European Research Council (ERC)—Seven Framework Program (ERC-2013-CoG 616050 to P.B.), by the Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale (INSERM). P.M.T was supported by the National Institutes of Health (ROI5GM120861 National Science Foundation (CBET 1040313) and the Albert B. Mounts Chair. A.J.M. was supported by NIH 5P50-OD019815. C.M.G. was supported partly by a stipend from the Pasteur–Paris University (PUPU) International PhD program and by the Institut Carnot Pasteur Maladies Infectieuses. D.S. benefited from a stipend (Poste d’accueil) provided by AP-HP, Paris, France and by the Institut Pasteur, Paris, France.

Author contributions

G.G., P.B., C.-H.L., and T.H.K. conceived and designed the research; C.-H.L., T.H.K., O.G., M.W., D.G., C.M.G., D.S., H.D., A.J.M., N.T., J.L., and E.M. performed experiments; G.G., P.B., C.-H.L., O.G., M.W., G.D., C.M.G., D.S., M.C., L.E.M., A.J.M., J.R.M.D., P.M.T., and A.S.M. analyzed data. G.G., P.B., C.-H.L., and G.D. wrote the paper. G.G. and P.B. provided funding.

Competing interests

G.G., C.-H.L., and T.H.K. have filed a patent application related to the Fc mutants described herein (PCT/US2019/0048078). The other authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41467-019-13108-2.

Correspondence and requests for materials should be addressed to P.B. or G.G.

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.